EKSO vs. ACST, BIOR, JAN, MRM, NNVC, UBX, NKGN, ONCT, ENLV, and ITRM
Should you be buying Ekso Bionics stock or one of its competitors? The main competitors of Ekso Bionics include Acasti Pharma (ACST), Biora Therapeutics (BIOR), JanOne (JAN), MEDIROM Healthcare Technologies (MRM), NanoViricides (NNVC), Unity Biotechnology (UBX), NKGen Biotech (NKGN), Oncternal Therapeutics (ONCT), Enlivex Therapeutics (ENLV), and Iterum Therapeutics (ITRM). These companies are all part of the "medical" sector.
Ekso Bionics (NASDAQ:EKSO) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Ekso Bionics received 7 more outperform votes than Acasti Pharma when rated by MarketBeat users. However, 70.52% of users gave Acasti Pharma an outperform vote while only 57.50% of users gave Ekso Bionics an outperform vote.
Ekso Bionics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
Acasti Pharma has a net margin of 0.00% compared to Ekso Bionics' net margin of -79.48%. Acasti Pharma's return on equity of -13.18% beat Ekso Bionics' return on equity.
Ekso Bionics has higher revenue and earnings than Acasti Pharma. Ekso Bionics is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.
6.4% of Ekso Bionics shares are owned by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are owned by institutional investors. 6.1% of Ekso Bionics shares are owned by insiders. Comparatively, 13.5% of Acasti Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Acasti Pharma had 3 more articles in the media than Ekso Bionics. MarketBeat recorded 3 mentions for Acasti Pharma and 0 mentions for Ekso Bionics. Acasti Pharma's average media sentiment score of 0.75 beat Ekso Bionics' score of 0.00 indicating that Acasti Pharma is being referred to more favorably in the news media.
Ekso Bionics currently has a consensus price target of $10.00, suggesting a potential upside of 640.74%. Acasti Pharma has a consensus price target of $6.00, suggesting a potential upside of 128.14%. Given Ekso Bionics' higher probable upside, analysts clearly believe Ekso Bionics is more favorable than Acasti Pharma.
Summary
Acasti Pharma beats Ekso Bionics on 8 of the 15 factors compared between the two stocks.
Get Ekso Bionics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EKSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ekso Bionics Competitors List
Related Companies and Tools
